An update from Mesoblast Limited ( (AU:MSB) ) is now available.
Mesoblast has successfully expanded the coverage of its FDA-approved therapy, Ryoncil, to over 100 million insured lives in the United States. This expansion includes Medicaid and commercial payers, highlighting the therapy’s growing acceptance and potential impact on treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients. The increased coverage is expected to enhance Mesoblast’s market position and provide broader access to its innovative treatment, potentially benefiting stakeholders and patients alike.
More about Mesoblast Limited
Mesoblast Limited is a global leader in developing allogeneic cellular medicines for severe inflammatory conditions. The company focuses on mesenchymal lineage cell therapy technology to treat conditions like steroid-refractory acute graft versus host disease (SR-aGvHD) and is expanding its product line to address other inflammatory diseases and conditions such as heart failure and chronic low back pain. Mesoblast has a strong intellectual property portfolio and manufacturing capabilities, with operations in Australia, the United States, and Singapore.
YTD Price Performance: -31.82%
Average Trading Volume: 400,962
Technical Sentiment Signal: Sell
Current Market Cap: $1.35B
For a thorough assessment of MSB stock, go to TipRanks’ Stock Analysis page.